Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 269-280

  Edelman, Robert ^a   Wasserman, Steven S ^a   Kublin, James G ^a   Bodison, Sacared A ^b   Nardin, Elizabeth H ^c   Oliveira, Giane A ^c   Ansari, Sobia ^c   Diggs, Carter L ^d   Kashala, Oscar L ^e   Schmeckpeper, Barbara J ^f   Hamilton, Robert G ^f  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^e Aquila Biopharmaceuticals Inc   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cutaneous immediate type hypersensitivity; Malaria vaccine; Phase I vaccine trial

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; MULTI ANTIGEN PEPTIDE VACCINE; QS 21; UNCLASSIFIED DRUG; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; RECOMBINANT VACCINE;

ADULT; ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ERYTHEMA; HEADACHE; HIGH RISK POPULATION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNIZATION; INFLAMMATION; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MALAISE; METHODOLOGY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVACCINATION; SENSITIZATION; SKIN TEST; SPOROZOITE; URTICARIA; VACCINATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN EXPERIMENT; HYPERSENSITIVITY; IMMUNOLOGY; INTRACUTANEOUS TEST; MALARIA FALCIPARUM; MALE; PAIN; PHASE 1 CLINICAL TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; ANTIGENS, PROTOZOAN; COHORT STUDIES; FEMALE; HUMAN EXPERIMENTATION; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTRADERMAL TESTS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PAIN; PLASMODIUM FALCIPARUM; URTICARIA; VACCINES, SYNTHETIC;

EID: 0037073595     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00468-1     Document Type: Article

References (44)

1. Institute of medicine. Malaria: Obstacles and Opportunities. Washington, DC: National Academy Press, 1991.
2. Marsh K. Malaria disaster in Africa. Lancet. 352(9132):1998;924.
3. Nussenzweig R.S., Zavala F. A malaria vaccine based on a sporozoite antigen. N. Engl. J. Med. 336(2):1997;128-130.
4. Brown A.E., Singharaj P., Webster H.K.et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine. 12(2):1994;102-108.
5. Sherwood J.A., Copeland R.S., Taylor K.A.et al. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine. 14(8):1996;817-827.
6. Kester K.E., McKinney D.A., Tornieporth N.et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183(4):2001;640-647.
7. Moreno C.A., Rodriguez R., Oliveira G.A.et al. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice. Vaccine. 18(1/2):1999;89-99.
8. Nardin E.H., Oliveira G.A., Calvo-Calle J.M.et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes. J. Infect. Dis. 182(5):2000;1486-1496.
9. Kublin J.G., Lowitt M.H., Hamilton R.G.et al. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine. 20(13):2002;1853-1861.
10. Kimura A, Sasazuki T. Reference protocol for the HLA DNA-typing technique. In: Tsuji KAMST, editor. HLA 1991, Proceedings of the Eleventh International Histocompatibility Workshop and Conference, Yokohama, Japan. Oxford: Oxford University Press, 1992. p. 397-419.
11. Calvo-Calle J.M., Hammer J., Sinigaglia F., Clavijo P., Moya-Castro Z.R., Nardin E.H. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 159(3):1997;1362-1373.
12. Nardin E.H., Herrington D.A., Davis J.et al. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science. 246(4937):1989;1603-1606.
13. Kensil C.R., Wu J.Y., Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm. Biotechnol. 6:1995;525-541.
14. Coughlin R.T., Fish D., Mather T.N., Ma J., Pavia C., Bulger P. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21. J. Infect. Dis. 171(4):1995;1049-1052.
15. Kitamura K. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc. Natl. Acad. Sci. U.S.A. 92(7):1995;2805-2809.
16. Hamilton RG, Adkinson NFJ. Measurement of total serum IgE and allergen-specific IgE antibody. In: Rose HR, de Macario EC, Fahey JL, Friedman H, Penn GM, editors. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology, 1992. p. 689-701.
17. Hamilton R.G., Adkinson N.F. Natural rubber latex skin testing reagents: safety and diagnostic accuracy of nonammoniated latex, ammoniated latex, and latex rubber glove extracts. J. Allergy Clin. Immunol. 98(5 Pt 1):1996;872-883.
18. Bousquet J, Michel F-B. In vivo methods for study of allergy. Skin tests, techniques, and interpretation. In: Middleton EJ, Reed CE, Ellis EF, Adkinson Jr NF, Yunginger JW, Busse WW, editors. Allergy Principles and Practice. St. Louis: Mosby, 1993. p. 573-94.
19. Waite D.C., Jacobson E.W., Ennis F.A.et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 19(28/29):2001;3957-3967.
20. CDC Fact Sheet, Hepatitis Branch. Atlanta, GA: National Center for Infectious Diseases, and National immunization Program, Centers for Disease Control and Prevention, 1998.
21. Sakaguchi M., Nakayama T., Fujita H., Toda M., Inouye S. Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin. Vaccine. 19(4/5):2000;431-436.
22. Blennow M., Granstrom M. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics. 84(1):1989;62-67.
23. Ratliff D.A., Burns-Cox C.J. Anaphylasix to tetanus toxoid. Br. Med. J. 288:1984;114.
24. Takahashi H., Pool V., Tsai1 T.F., Chen R.T. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine. 18(26):2000;2963-2969.
25. Plesner A.M., Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine. 15(11):1997;1239-1243.
26. Tsai T.F. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine. 18(Suppl 2):2000;1-25.
27. Karaayvaz M., Ozanguc N. Recall urticaria: a case report. J. Allergy Clin. Immunol. 97(6):1996;1419-1420.
28. Rinn K., Schiffman K., Otero H.O., Disis M.L. Antigen-specific recall urticaria to a peptide-based vaccine. J. Allergy Clin. Immunol. 104(1):1999;240-242.
29. Bernstein I.L. Proceedings of the task force on guidelines for standardizing old and new technologies used for the diagnosis and treatment of allergic diseases. J. Allergy Clin. Immunol. 82:1988;487-526.
30. Wood R.A., Phipatanakul W., Hamilton R.G., Eggleston P.A. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J. Allergy Clin. Immunol. 103(5 Pt 1):1999;773-779.
31. Portnoy J.M., Moffitt J.E., Golden D.B.et al. Stinging insect hypersensitivity: a practice parameter. J. Allergy Clin. Immunol. 103(5 Pt 1):1999;963-980.
32. Ballou W.R., Hoffman S.L., Sherwood J.A.et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1(8545):1987;1277-1281.
33. Keitel W.A., Kester K.E., Atmar R.L.et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 18(5/6):1999;531-539.
34. Shahabuddin S., Ponath P., Schleimer R.P. Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C chemokines. J. Immunol. 164(7):2000;3847-3854.
35. Kay A.B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344(1):2001;30-37.
36. Stoute J.A., Slaoui M., Heppner D.G.et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336(2):1997;86-91.
37. Amador R., Moreno A., Murillo L.A.et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis. 166(1):1992;139-144.
38. Alonso P.L., Smith T., Schellenberg J.R.et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet. 344(8931):1994;1175-1181.
39. Teuscher T., Schellenberg J.R., Bastos dA I.et al. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine. 12(4):1994;328-336.
40. Noya O., Gabaldon B.Y., Alarcon D.N.et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170(2):1994;396-402.
41. Nosten F., Luxemburger C., Kyle D.E.et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet. 348(9029):1996;701-707.
42. Nosten F., Luxemburger C., Kyle D.E.et al. Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia. Am. J. Trop. Med. Hyg. 56(5):1997;526-532.
43. Gordon D.M., Duffy P.E., Heppner D.G.et al. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Am. J. Trop. Med. Hyg. 55(1):1996;63-68.
44. Kashala O., Amador R., Valero M.V.et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine. 20(17/18):2002;2263-2277.